Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Vemurafenib Plus Cobimetinib Continuous Versus Intermittent, in Previously Untreated BRAFV600- Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

NCT02583516 is registered in ClinicalTrials.gov with Grupo Español Multidisciplinar de Melanoma as lead sponsor.

NCT NCT02583516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02583516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Vemurafenib Plus Cobimetinib Continuous Versus Intermittent, in Previously Untreated BRAFV600- Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Lead sponsor
Grupo Español Multidisciplinar de Melanoma
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2015
Completion date
September 30, 2019
Enrollment
70 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma